United StatesThe article discusses growing concerns over the U.S.-China biotech rivalry, highlighting China's rapid rise as a major player in drug development and innovation. According to data from Pharmcube, China accounts for 34% of new drugs in global clinical development, surpassing the U.S.'s 27%, and contributes to 40% of new drugs entering clinical stages annually. Additionally, China's out-licensing deals have surged to $137.7 billion between 2021 and 2025. The author, a longtime biotech journalist based in both the U.S. and China, expresses concern over the potential negative impact of U.S. policies targeting Chinese biotech firms, which could harm collaboration and innovation in the field.
Bias read (Left): The article frames the U.S.-China biotech competition as a potential threat to scientific collaboration and innovation, emphasizing the risks posed by restrictive policies toward China. It highlights China's contributions to global drug development and raises concerns about the broader implications,
